Alps Group Business Summary

Alps Group Inc (NASDAQ: ALPS) operates as a fully integrated biotechnology and life sciences platform specializing in predictive, preventive, and precision medicine. The company generates revenue through a diversified model encompassing diagnostic testing fees, wellness service subscriptions, and the commercialization of advanced therapies. Its primary business segments include Molecular Diagnostics (genomics and mRNA technologies), Cellular Therapy (GMP-certified manufacturing of autologous NK cells and stem cell exosomes), and Healthcare Services, which are delivered through its proprietary medical and wellness centers. Positioned as a leading "bench-to-bedside" innovator in Southeast Asia, Alps Group competes with global biotech firms such as Sangamo Therapeutics, Anika Therapeutics, and ProQR Therapeutics, distinguishing itself through an integrated ecosystem that bridges clinical research with direct patient care. The leadership team is anchored by Founder, Chairman, and Group CEO Dr. Tham Seng Kong, a veteran in cellular therapy and oncology with over two decades of research experience. Key executives include Chief Financial Officer Cheing Lye-Ping (Penny), appointed in January 2026 to oversee global fiscal strategy, and Chief Operating Officer Low Wei Sim (Amanda), who manages the group’s healthcare and wellness operations. Scientific advancement is led by Chief Scientific Officer Prof. Manickam Ravichandran and Chief Vaccine Development Officer Prof. Poh Chit Laa. Following its October 2025 Nasdaq listing via a business combination with Globalink Investment Inc., the company maintains a strong institutional investor base, including Millennium Management, Citadel Advisors, and Jane Street Group, while the board features notable independent directors such as former Malaysian Parliament member Tan Sri Suleiman bin Mohamed.